to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease
Always consult with a qualified healthcare provider for any questions about your health or treatment
Clinical Therapeutics, 15(6), 1065-1076
Tirzepatide vs semaglutide Single receptor (GLP-1) 15-17% weight loss average Lower starting dose (0.25mg) Slower titration More established research Tirzepatide : Dual receptor (GLP-1 + GIP) 15-22% weight loss average Higher starting dose (2.5mg) Faster results Newer, less long-term data Winner : Tirzepatide edges out for weight loss effectiveness
Heraa Chaudhry, MD, is a board-certified family medicine physician with more than a decade of clinical experience, specializing in preventative medicine, womens health, and integrative wellness